SCYNEXIS, Inc. to Present at Upcoming Investor Conferences

Nov 20, 2018

SCYNEXIS Reports Third Quarter 2018 Financial Results and Provides Company Update

Nov 13, 2018

SCYNEXIS Announces FDA Agreement with Company-Proposed Phase 3 Vulvovaginal Candidiasis Program for Oral Ibrexafungerp

Oct 23, 2018

SCYNEXIS, Inc. Announces First Patient Dosed in Phase 3 Open-label Study Evaluating Oral Ibrexafungerp in Candida auris Infections (CARES)

Oct 15, 2018

SCYNEXIS Supports AMR Challenge and Fungal Disease Awareness Week

Oct 1, 2018

SCYNEXIS to Present an Overview of the Company's Pipeline at IDWeek 2018

Sep 26, 2018

SCYNEXIS, Inc. to Present at Upcoming Investor Conferences

Sep 25, 2018

SCYNEXIS, Inc. Presents Ibrexafungerp Data at the 2018 ESCMID/ASM Conference on Drug Development

Sep 4, 2018

SCYNEXIS, Inc. to Participate in Upcoming Investor Conferences

Aug 29, 2018

SCYNEXIS Reports Second Quarter 2018 Financial Results and Provides Company Update

Aug 9, 2018